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Abstract
Background: Amyotrophic lateral sclerosis is a rapidly progressive neurodegenerative disorder characterised by loss
of motor neurons leading to severe weakness and death from respiratory failure within 3-5 years. Riluzole prolongs
survival in ALS. A published report has suggested a dramatic effect of lithium carbonate on survival. 44 patients
were studied, with 16 randomly selected to take LiCO3 and riluzole and 28 allocated to take riluzole alone. In the
group treated with lithium, no patients had died (i.e., 100% survival) at the end of the study (15 months from
entry), compared to 71% surviving in the riluzole-only group. Although the trial can be criticised on several
grounds, there is a substantial rationale from other laboratory studies that lithium is worth investigating
therapeutically in amyotrophic lateral sclerosis.
Methods/Design: LiCALS is a multi-centre double-blind randomised parallel group controlled trial of the efficacy,
safety, and tolerability of lithium carbonate (LiCO3) at doses to achieve stable ‘therapeutic’ plasma levels (0.4-0.8
mmol/L), plus standard treatment, versus matched placebo plus standard treatment, in patients with amyotrophic
lateral sclerosis. The study will be based in the UK, in partnership with the MND Association and DeNDRoN (the
Dementias and Neurodegnerative Diseases Clinical Research Network). 220 patients will be recruited. All patients
will be on the standard treatment for ALS of riluzole 100 mg daily. The primary outcome measure will be death
from any cause at 18 months defined from the date of randomisation. Secondary outcome measures will be
changes in three functional rating scales, the ALS Functional Rating Scale-Revised, The EuroQOL (EQ-5D), and the
Hospital Anxiety and Depression Scale.
Eligible patients will have El Escorial Possible, Laboratory-supported Probable, Probable or Definite amyotrophic
lateral sclerosis with disease duration between 6 months and 36 months (inclusive), vital capacity ≥ 60% of
predicted within 1 month prior to randomisation and age at least18 years.
Discussion: Patient recruitment began in June 2009 and the last patient is expected to complete the trial protocol
in November 2011.
Trial registration: Current controlled trials ISRCTN83178718
* Correspondence: ammar.al-chalabi@kcl.ac.uk
1MRC Centre for Neurodegeneration Research, King’s College London,
Department of Clinical Neuroscience, London SE5 8AF, UK
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Background
Amyotrophic lateral sclerosis (ALS; motor neuron dis-
ease, MND) is a rapidly progressive neurodegenerative
disorder characterised by loss of corticospinal tract
motor neurons and spinal anterior horn motor neurons
leading to severe weakness and death from respiratory
failure usually within 3-5 years [1]. In about 5% of cases
there is a family history of ALS, and in about a quarter of
such cases, mutation in the SOD1, TARDBP, FUS or
OPTN genes is responsible. ALS is the first neurodegen-
erative disease to provide hope that neuroprotective stra-
tegies may be feasible. Riluzole prolongs survival in ALS
with a reduction in mortality of ~7% at 18 months for
100 mg daily riluzole versus placebo and a relative risk
reduction of ~35% [2-4]. Riluzole has been licensed by
the MHRA and approved by NICE http://www.nice.org.
uk. Nonetheless there remains a pressing need for effec-
tive treatments that further slow disease progression,
while maintaining quality of life.
Any drug that can be shown to slow the course of ALS
in a clinically significant way and to be safe and well tol-
erated will be an important advance for patients with this
disease. A published report has suggested a dramatic
effect of lithium carbonate on survival, albeit in a very
small group of patients [5]. 44 patients were studied, with
16 randomly selected to take LiCO3 and riluzole and 28
allocated to take riluzole alone. In the group treated with
lithium, no patients had died (i.e., 100% survival) at the
end of the study (15 months from entry), compared to
71% surviving in the riluzole-only group. The difference
in survival was significant at 12 and 15 months. There
were also significant differences in the rate of functional
deterioration measured by MRC Manual Muscle Testing
scores (MMT; 18% decline in LiCO3 + riluzole group
versus 35% in the riluzole only group), the Norris scale
(11% versus 46%), ALSFRS-R (14% versus 40%), and
forced vital capacity (FVC; 14% versus 33%).
Unfortunately, the trial design can be criticised on sev-
eral counts. First, the patients were not well matched for
age, the LiCO3 group being approximately three years
younger at age of onset than the control (riluzole only)
group, which is known to be a prognostic factor. Secondly,
and crucially, the groups were not truly randomised, but
‘randomly selected’- no details of how this was done were
provided, although the authors stated that patients were
selected on the basis of matched forced vital capacity and
pattern of clinical presentation. The study was single-
blind, with the physicians carrying out the functional
assessments being blinded. Adjustments of plasma lithium
levels were carried out by an unblinded observer, and the
patients were not blinded. The dose of lithium carbonate
ranged from 300 mg to 450 mg daily, with plasma lithium
levels targeted to reach 0.4-0.8 mmol/l.
ALS is a heterogeneous disease, and each group of
patients entering a trial will differ, to a greater or lesser
extent, in the average rate of progression measured by
death or by measures of function such as the ALSFRS-R.
The smaller the sample, the greater is the chance that
there will be major differences in average rates of pro-
gression between treatment groups. While large samples
and true randomisation will usually balance differences
in prognostic factors such as the anticipated rate of dis-
ease progression between patients taking the active drug
or placebo, this is not always the case [6,7]. Even in large
randomised trials in which patients are recruited using
standardized entry criteria, there are patients with slow
disease progression as well as patients with a high risk of
dying before the end of the study [3,4,6]. It is therefore
possible, by chance, to select a small group of patients
with unusually good prospects for survival. On the other
hand, despite the weaknesses of trial design, the size of
the observed difference between the lithium and control
groups (i.e., the assumed drug effect) is difficult to
explain on the basis of imbalance of major prognostic
factors alone.
The same study [5] also included a series of experi-
ments in mice transgenic for the G93A Superoxide Dis-
mutase 1 (SOD1) mutation, known to cause ALS in
humans. There was a prolonged mean survival time (p <
0.001) and increased disease duration (p = 0.05) with
lithium treatment compared to saline treatment, starting
at 75 days of age. The mean survival time in the lithium
group was 148 ± 4.3 days (n = 20), compared to 110.8 ±
5 days (n = 20) in vehicle treated mice, representing
~36% increase in lifespan. Disease duration was increased
from a mean of 9 days to more than 38 days (i.e., > 300%)
in lithium compared to vehicle treated mice.
The authors comment that even when lithium treat-
ment was started at the onset of motor symptoms there
was still a comparable increase in disease duration, but
these data were not shown. In addition, lithium delayed
the onset of paralysis and limb adduction and also
improved function on tests such as rotarod, grip strength
and stride length. The authors found that lithium treat-
ment increased the number of surviving a motor neurons
in the G93A mice and had a number of other effects on
pathological changes including increasing the numbers of
Renshaw-like neurons in the spinal cord. They hypothe-
sised that this was mediated through an effect on neuro-
genesis, since lithium has been reported to produce
neurogenesis in physiological conditions in the hippo-
campus, albeit not in the spinal cord. They also reported
that lithium rescues spinal cord mitochondria and facili-
tates the clearance of a-synuclein, ubiquitin and SOD1,
and that it increases the number of autophagic vacuoles
in the spinal cord.
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There is a substantial rationale from other laboratory
studies that lithium is worth investigating therapeutically
in ALS. One previous study also identified a modest pro-
tective effect of lithium in the ALS transgenic mouse [8].
Lithium has been shown to have neuroprotective effects
in several models of neurodegeneration through a variety
of mechanisms [9,10]. The kinesin light chain, a key com-
ponent of the cellular motor mediating fast anterograde
axonal transport, is a substrate for glycogen synthase
kinase 3 Beta (GSK3b) [11-13] and lithium reverses defi-
cits in axonal transport in a microtubule-associated pro-
tein tau (MAPT) over-expression model in drosophila
[14]. Fast axonal transport of mitochondria is impaired
by SOD1 mutations, resulting in a maldistribution of
mitochondria in the neuron [11] so lithium might coun-
teract this.
The neuroprotective effects of lithium are thought to
be mediated to some degree and in some models through
GSK3b inhibition [9,10,15,16] but also by modification of
NMDA-subtype glutamate receptor function through
inhibition of NR2B tyrosine phosphorylation [17], activa-
tion of cell survival factors such as the PI 3- kinase/Akt
signalling pathway, [1] the induction of neurotrophic
proteins, including brain-derived neurotrophic factors
(BDNF) [9,18,19] and up-regulation of heat-shock pro-
tein and Bcl-2 [9,20-23]. Lithium enhances neurogenesis
in various experimental systems [5,24]. In addition,
lithium may promote autophagy through the inhibition
of inositol-monophosphatase-15, and thus through the
neuroprotective effects of autophagy in neurodegenera-
tion [25-28]. However, the effects of lithium on autop-
hagy are complex, as lithium may reduce autophagy by
inhibiting GSK3b, but stimulate it by inducing the mam-
malian target of rapamycin (mTOR)-dependent autop-
hagy [26]. Thus combinations of lithium with agents that
inhibit mTOR may prove more useful in neuroprotection
than lithium alone. We have no data on possible interac-
tions between lithium and riluzole.
Thus, despite reservations regarding the strength of the
clinical trial data, there is a strong argument to carry out
a phase II/III study of LiCO3 in ALS. We take the view
that such a study should be powered to detect a large
effect, i.e., close to that observed in the original human
study [5].
There are various systematic reviews of neuroprotec-
tive strategies in ALS, as well as Cochrane systematic
reviews of riluzole and failed treatments [29]. In essence,
apart from Riluzole, none of the many agents tested
have had any positive effect on survival or function in
ALS, and there remains a pressing need for disease-
modifying therapy, the aim being to slow disease pro-
gression while maintaining reasonable quality of life, in
conjunction with symptomatic treatments and palliative
care.
It is hoped that results from our study will be used to
inform decisions of whether lithium should be added to
riluzole in the routine management of patients with ALS,
to improve their survival, motor function and quality of
life without significant adverse effects.
The protocol includes dose titration and monitoring to
achieve therapeutic plasma levels of > = 0.4- < = 0.8
mmol/L.
Lithium has been prescribed in long term use over many
decades for other patient groups [30]. Because the effective
dose is fairly close to the toxic dose, it is necessary to con-
duct careful dose titration [30-32]. We have taken advice
on initiation and monitoring of therapy from senior psy-
chiatrists with extensive expertise in the pharmacology
and clinical use of lithium therapy and will follow the
NICE guidelines (http://www.nice.org.uk, Guideline No
38, 2006). The protocol will also involve un-blinded “safety
monitoring” physicians who will be responsible for moni-
toring lithium levels and assessing patients for all aspects
of safety and possible toxicity.
Methods/Design
For further detail please see Additional File 1.
Primary Objective
To determine whether lithium carbonate (LiCO3), in doses
achieving blood levels of 0.4-0.8 mmols/L, combined with
standard ALS treatment, significantly prolongs survival in
ALS over 18 months, compared with standard treatment
alone.
Secondary Objectives
To monitor the safety of treatment with LiCO3 over 18
months.
To determine whether treatment with LiCO3 slows
the rate of functional deterioration over 18 months.
To determine whether treatment with LiCO3 affects
quality of life (QoL) or mental state (anxiety, depression)
in patients with ALS, over 18 months
Study Design
LiCALS is a multi-centre (UK) double-blind randomised
parallel group controlled trial of the efficacy, safety, and
tolerability of lithium carbonate (LiCO3) at doses to
achieve stable ‘therapeutic’ plasma levels (0.4-0.8 mmol/L),
plus standard treatment, versus matched placebo plus
standard treatment, in patients with ALS. The study will
be based in the UK, in partnership with the MND Associa-
tion and DeNDRoN.
A total of 220 patients will be recruited. All patients will
be on the standard treatment for ALS (riluzole 100 mg
daily) as per routine clinical practice. The study will evalu-
ate the efficacy and safety of lithium carbonate given
orally, combined with standard treatment, compared to
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matched placebo with standard treatment. All participants
involved will be required to be taking a stable dose of rilu-
zole 50 mg orally twice daily for at least 28 days (four
weeks) prior to screening. All participants will be con-
sented in accordance with the declaration of Helsinki. The
study has been approved by the South East Research
Ethics Committee (reference 09/H1102/15). Following
consent, participants will be randomised 1:1 to either
LiCO3 plus standard treatment or matched placebo plus
standard treatment.
Primary outcome measure
Death from any cause at 18 months defined from the
date of randomisation.
Death will be assessed by 3 monthly (telephone) status
reports and by standard clinic reports and confirmed by
written evidence from the trial staff or general practi-
tioner, and a death certificate will be obtained for all
deaths. Further ascertainment of status will be sought
from the NHS Information Centre tracing service if
required, to avoid loss to follow-up of this primary out-
come. Previous trials obtained 100% ascertainment of
death through death certificates (i.e., obtained for every
death) and documented survival at cut-off for surviving
patients.
Secondary outcome measures
Slope of ALS Functional Rating Scale-Revised (ALSFRS-R)
scores
[32,33]
Functional measures (ALSFRS-R) will be assessed at
visits by blinded trained trial staff, according to standard
operating procedures (SOPs).
Change in EuroQOL (EQ-5D)
A standardised instrument for use as a measure of health
outcome, describing states of health in five dimensions:
mobility, self-care, usual activities, pain or discomfort
and anxiety or depression [34,35].
Change in Hospital Anxiety and Depression Scale (HADS)
A 14 item questionnaire, designed to detect the presence
and severity of mild degrees of mood disorder, anxiety and
depression [36].
The ALSFRS-R [32,37] and EQ-5D [38] are validated
for telephone use.
Definition of end of study
The end of the study will be the last participant’s final
study contact, at final visit (month 18/week 77).
SAEs will be monitored for a further 30 days after stop-
ping the trial treatment, or until resolution.
The open label extension study will commence when
the first patient completes Month 18 (week 77) and will
run in parallel with the double blind study until the
completion of the double blind primary analysis.
Subject Population
Inclusion criteria Patients with Possible, Laboratory-
supported Probable, Probable or Definite ALS according
to the revised version of the El Escorial World Federa-
tion of Neurology criteria (The ‘Airlie House Statement’:
http://www.wfnals.org)
These criteria are internationally accepted research
diagnostic criteria with high specificity and sensitivity.
The onset form (bulbar or limb) and disease type (famil-
ial or sporadic) will be recorded; source documents will
include a full report of an electromyogram (EMG)
reported by an experienced neurophysiologist as compa-
tible with ALS. The neurological exam should be per-
formed by a physician.
Disease duration ≥ 6 months and ≤ 36 calendar
months (inclusive), with disease onset defined as date of
first muscle weakness, or dysarthria. SVC ≥ 60% of pre-
dicted within 1 month prior to randomisation
Age: ≥ 18 years (inclusive). In the case of a female with
childbearing potential, the patient must not be pregnant
or breast-feeding. Women of childbearing potential will
have a urine pregnancy test before randomisation; and at
each clinic visit. The results of those must be negative.
Women of childbearing potential should use adequate
contraception. Patients should be continuously treated
with riluzole for at least 4 weeks prior to screening (28
days inclusive) and stabilised at 100 mg/day (50 mg bid)
without significant adverse drug reactions. Trial partici-
pants should be capable of understanding the informa-
tion given and giving fully informed consent prior to any
study specific procedures.
Exclusion criteria Participation in another therapeutic
study within the preceding 12 weeks or use of other
investigational drugs or agents. Tracheostomy, or assisted
ventilation of any type during the preceding three
months. Existing gastrostomy, unless elective and not
currently used for nutritional support or hydration. Any
medical condition known to have an association with
motor neuron dysfunction which might confound or
obscure the diagnosis of ALS. Presence of any concomi-
tant life-threatening disease or any disease or impairment
likely to interfere with functional assessment. Confirmed
hepatic insufficiency or abnormal liver function (ALT
greater than 1.5 times the upper limit of the normal
range) within one month of randomisation. That blood
test may be repeated in the case of initial abnormal
results; if the levels return to normal, the patient may
then be included in the study. Renal insufficiency (serum
creatinine ≥ ULN for the centre/local laboratory) within
one month of randomisation. Recorded diagnosis or evi-
dence of major psychiatric disorder or clinically evident
dementia. Known allergy or hypersensitivity to lithium,
or its excipients. Likely to be uncooperative or to fail to
Al-Chalabi et al. BMC Neurology 2011, 11:111
http://www.biomedcentral.com/1471-2377/11/111
Page 4 of 14
comply with the trial requirements or to be inaccessible
in the event of an emergency. Subjects with significant
haematological, biochemical and autoimmune abnormal-
ities, as judged by the study physician. If a woman of
childbearing potential, unable or unwilling to use effec-
tive contraception during the study. Patients with active
inflammation/infection at screening or Baseline (Day 0).
Patients presenting with active inflammation/infection
can be reassessed at a later date, and included in the trial
if the infection/inflammation has cleared. Patients already
taking lithium in any form. Presence of a medical condi-
tion contra-indicative to the use of lithium, according to
the BNF http://www.bnf.org/bnf/
Screening, Recruitment and Consent
Patients will be identified through clinics at each of the
10 centres, which are all regional MND Care Centres.
They will be given the patient information sheet to read,
and will have 7-14 days to decide whether to participate
in the study. At clinic, there will be opportunity for the
participants to ask questions of a member of staff trained
in all trial procedures, as delegated by the PI. The Princi-
pal Investigator at each site will ensure that the partici-
pants meet the inclusion and exclusion criteria at the
point of screening.
After signing the consent form, participants will have
blood tests to measure their thyroid function, detect any
renal and hepatic insufficiency, any haematological, bio-
chemical or immunological abnormalities, and their SVC
will be measured. If they are a woman of childbearing
potential, they will have a urine pregnancy test at each of
their clinic visits. Those procedures should be done
within one month prior to randomisation.
A screening log will be kept at site to document details
of patients invited to participate in the study. For patients
who decline or are ineligible, this will document any rea-
sons available for non-participation (where provided).
The log will ensure potential participants are only
approached once.
The original signed consent form will be retained in the
Investigator Site File, with a copy in the participant’s hos-
pital medical notes, and a copy provided to the participant.
The participant will specifically consent to their GP being
informed of their participation in the study.
The right to refuse to participate without giving rea-
sons will be respected.
Study Medication
Description of Randomised Treatments
Placebo
Matching placebo tablets will be manufactured for the
295 mg lithium carbonate tablets. These will be identical
in appearance to the active tablets-white tablets of tablets
of approximately 1.1 cm in diameter, with a break notch
on one side.
Lithium Carbonate
The experimental intervention is lithium carbonate, in
combination with normal standard treatment for ALS
(riluzole 50 mg bd). Lithium carbonate is licensed for
the treatment and prophylaxis of mania, bipolar disorder
(manic-depressive disorder), recurrent depression, and
the control of aggressive or self-mutilating behaviour.
Within the context of this study, lithium carbonate will
be used in a new target population.
Reported side effects of lithium carbonate are given
later.
Selection of Doses for the Trial The study medication
is being used within normal clinical doses. The medica-
tion will be titrated to achieve a blood plasma level of ≥
0.4- ≤ 0.8 mmol/l.
Selection & Timing of Dose for Each Participant
Interventions will be available in 295 mg tablets of
lithium carbonate or matching placebo.
Tablets will be taken once daily, starting with one tablet
(295 mg daily) initially, titrated up to two or three tablets
daily over the first four weeks of treatment, depending on
blood lithium levels. Blood levels will be measured at base-
line, 7 days (12 hours +/-30 minutes after previous evening
dose), and at 14 days (12 hours +/-30 minutes after
previous evening dose). The target range for the lithium
plasma level will be between ≥ 0.4 mmol/l and ≤
0.8 mmol/l. Further plasma level measurements will be
taken at 21 and 28 days to confirm the target range has
been achieved. Ongoing lithium level monitoring will be
scheduled for week 8 and week 12, and 3 monthly there-
after for the duration of the study.
Dose adjustments can be made by reducing back to 2
tablets daily or to 1 tablet daily as required. It is antici-
pated that most patients will remain on 2 tablets
throughout the duration of the trial.
Sham dose adjustments will also be made to patients
on placebo to maintain blinding in clinical sites as per
SOP.
Blinding of Investigational Medicinal Product Active
study medication (Lithium carbonate) and placebo will
be identical.
Identity & Supply of Investigational Medicinal Pro-
duct Lithium carbonate-Apogepha (Germany)
The trial medication is supplied as white tablets of
approximately 1.1 cm in diameter. There is a break
notch on one side of the tablets.
Packaging & Labelling of Investigational Medicinal
Product Active study medication and placebo will be
supplied in blisters of 21 tablets. For months 1, 2 and 3,
five blisters will be packaged into 1 month kits. 3 of these
kits, each bearing the same kit number, will be packaged
together and dispensed directly to the study site.
Thereafter, 14 individual blisters will be supplied in 3-
monthly patient kits for months 4-6, 7-9, 10-12, 13-15
and 16-18. Each of those kits will have a different kit
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number. Packaging and labelling will be completed in
accordance with Good Manufacturing Practice (GMP)
Annex 13 requirements and GCP, by Haupt Pharma,
Brackenheim, Germany.
Prescription of Investigational Medicinal Product
Study medication will be prescribed by an authorised
study physician according to the protocol, using a trial
specific prescription. Medication will be dispensed
according to local pharmacy practice.
Participants will be informed of potential adverse reac-
tions and advised to seek medical help and contact the
research team, if required. Patients will carry cards with
an emergency 24 hour code break number (Guy’s Medi-
cal Toxicology Unit, (0)207 358 9167), which will also
be printed on the study medication packs.
Documentation of prescribing, dispensing and return
of study medication shall be maintained for study
records in the pharmacy file and reconciled with the
investigator site file at the end of the study.
Dispensing & Distribution of Investigational Medic-
inal Product Study drug will be stored in a secure area
with limited access within each local pharmacy according
to the storage requirements documented on the clinical
trial label (store in the original package and protected
from moisture), prior to dispensing for each participant’s
baseline visit. A temperature log will be maintained as
per local pharmacy procedures.
Study medication will be distributed to the 10 study site
pharmacies by and from Haupt Pharma, Brackenheim,
Germany. Study medication receipt will be recorded in the
study pharmacy file. A study medication dispensing and
return log will be maintained by the site pharmacies.
Supplies of the study medications will be dispensed to
the patient at Months 0, 1, 2, 3, 6, 9, 12 and 15.
Administration of Investigational Medicinal Product
Tablets will be taken by participants using their normal
methods for medicines management in a single dose at
night. Participants will be provided with written infor-
mation from the doctor detailing the dose to be taken.
Following stabilisation of blood levels over the first 3
months, plasma level monitoring can be measured every
3 months, except in the following circumstances, when
monitoring needs to be done more frequently: presence
of intercurrent illness, symptoms or signs of lithium toxi-
city, or if the patient is taking interacting drugs e.g. non-
steroidal anti-inflammatory agents, diuretics, steroids,
metronidazole, tetracycline, angiotensin converting
enzyme (ACE) inhibitors; or if there is a change in fluid
or sodium intake. If the study medication is given
crushed via a feeding tube, as opposed to as whole
tablets, monitoring of Li Levels will also need to be more
frequent. All medication will be monitored by a lithium
physician (unblinded).
Unused Trial Study Medication & Study Medication
Accountability
At the end of each visit (months 1, 2, 3, 6, 9, 12,15, and
18) participants will be asked to return any surplus
study drug in the original packaging to the research
team, who will verify and document compliance and dis-
cuss any discrepancies immediately with the participant.
All unused study medication and packaging will then be
sent to the local pharmacy where the study monitor will
check and arrange collection of returns. Monitoring
checks will be carried out between the eCRF and phar-
macy to ensure the number of tablets returned is cor-
rectly documented.
Concomitant Medications All concomitant drug thera-
pies received will be recorded at baseline and follow-up
assessment.
Contraindications include hypersensitivity to lithium
or to any of the excipients.
Lithium can cause neurotoxicity, which can happen
without an increase in blood lithium levels. Neurotoxi-
city usually follows interaction with medications; drugs
implicated include selective serotonin reuptake inhibi-
tors (SSRIs), calcium channel blockers, carbamazepine,
phenytoin, neuroleptics and methyldopa. The protocol
will therefore involve a lithium physician (unblinded)
who will be responsible for monitoring lithium levels
and making dose adjustments as described later. The
treating physician (blinded) will assess patients, review
adverse events, and consider possible toxicity. Details of
all other agents that might interact with lithium can be
found in the British National Formulary (BNF) http://
www.bnf.org/bnf/.
The treating physician (blinded) will be provided with
an emergency 24 hr unblinding contact number (Guy’s
Medical Toxicology Unit, 0207 358 9167).
Participants should not receive any other investigational
drugs or agents during their participation in the study.
Safety Monitoring The following blood tests will be
done at regular intervals throughout the study, as indi-
cated in Table 1.
Routine haematology: white blood cell count and differ-
ential (eosinophils, basophils, neutrophils, lymphocytes
and monocytes), red blood cell count and indices (PCV,
MCV, MCH, MCHC), haemoglobin, platelets; biochemis-
try: (including liver and renal function), alkaline phospha-
tase, bilirubin, albumin, sodium, potassium, calcium,
corrected calcium, phosphate, total protein, globulin, urea,
serum creatinine, ALT. Thyroid function will be assessed
by measurement of thyroid stimulating hormone.
Haematology, biochemistry, thyroid function and
lithium levels can be done within 28 days pre-randomi-
sation or at baseline. All results must be available prior
to the patient being randomised.
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Method of Identification of Patients Patient identifica-
tion number will be allocated by registering the patient
on the MACRO eCRF system, after consent has been
signed. The system will generate a unique identifier to
be used throughout the study.
The PIN will be a five digit number; the initial two
digits indicate the centre
(Birmingham = 01; King’s College Hospital = 02;
Liverpool = 03; Manchester = 04; National Hospital for
Neurology and Neurosurgery = 05; Newcastle = 06;
Oxford = 07; Plymouth = 08; Preston = 09; Sheffield =
10), and then a three-digit number indicating the num-
ber within the centre.
Method of Randomisation Patients will be allocated to
placebo or lithium carbonate (ratio 1:1) by sites via an
online system based at the Mental Health & Neu-
roscience Clinical Trials Unit (MH&N CTU) based at the
Institute of Psychiatry. The randomisation website
address is https://ctu.iop.kcl.ac.uk/randomisations/login.
asp
Allocation will be stratified by centre and site of disease
onset, by stratified block randomisation with randomly
varying block sizes.
Only site staff authorised to request randomisation
will be sent passwords for the randomisation system.
Requests for passwords are via the trial manager to the
MH&N CTU.
Implementation Procedures Blinded packs of study
medications will be sent to the site pharmacies.
Once an eligible patient has completed the baseline
assessment and provided written informed consent,
online randomisation will be requested by site. Emails
confirming the treatment kit allocation will automatically
be generated to the requestor, the site PI, the site phar-
macist and the trial manager. A study specific prescrip-
tion will be completed and sent to pharmacy for
dispensing. The confirmation e mail will be attached to
the study prescription, and cross-checked against it, at
the point of dispensing.
For baseline, week 4 and week 8 visits, this initial treat-
ment kit number will be used for prescribing study
medication.
For months 3, 6, 9, 12 and 15, the online system must be
accessed again and a new kit number allocated per patient
per visit.
Each kit will correspond to the appropriate study arm
the patient was randomised to receive.
Any problems with the online randomisation system
should be reported to the trial manager or to the
MH&N CTU at the email address below:
Contact details for Randomisation: Randomization_
request@iop.kcl.ac.uk.
Blinding Assignment to either lithium carbonate or pla-
cebo will be blinded to the participants, investigators and
pharmacy (double-blind). Blinding of patients and treat-
ing physicians to allocation status will be assured by
identical tablet appearance, by identical labelling between
placebo and doses of active drug, and by sham dosage
adjustments made by a lithium physician (unblinded) in
the control group to mirror titration of lithium dosage in
the intervention group. For safety reasons, lithium physi-
cians (unblinded) will monitor plasma lithium levels,
safety bloods, and symptoms. Every effort will be made to
maintain strict blinding, although for practical reasons,
the unblinded lithium physicians will be part of the same
unit as the treating physicians (blinded).
A set of sealed code-break envelopes will be prepared by
Haupt Pharma and sent to Guy’s Medical Toxicology
Unit; these envelopes should be opened only where knowl-
edge of the randomised treatment is needed to optimise
the clinical management of the patient. Code breaks will
not be routinely opened for participants who complete
study treatment.
A sealed randomisation list will also be held by
MH&N CTU as back-up.
If a request for code break is received from a physi-
cian (e.g. the patient’s general practitioner) outside the
research team, Guy’s Medical Toxicology Unit will
attempt to contact the research team to verify the
request before the code is broken.
If the code is broken, details including patient study
number, the date code break was performed, the person
who broke the code, and reason for code break shall be
recorded on a record card within the code break envel-
ope and maintained. If clinically indicated, the partici-
pant will be withdrawn from study medication.
Accidental unblindings will be dealt with on a case by
case basis, if and when they arise. We will continue to
collect the patient’s data according to the visit schedule,
unless the patient withdraws their consent.
Table 1 Safety Blood Tests
Phase Pre-Randomisation Weekly visits Monthly visits W/l
Blood test Wk -4 to Day 0 0 1 2 3 4 8 3 6 9 12 15 18 Withdrawal
Haematology x x x x x x x x x
Biochemistry x x x x x x x x x x x x
Thyroid Function x x x x
Li Levels x x x x x x x x x x x x x x
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Study Data
Trial Database An electronic Case Report Forms
(eCRF) will be created using the InferMed Macro sys-
tem. This system is regulatory compliant (GCP,
21CRF11, EC Clinical Trial Directive). The eCRF will be
created in collaboration with the trial statisticians and
the investigators and maintained by the MH&N Clinical
Trials Unit. It will be hosted on a dedicated secure ser-
ver within KCL.
Source data will be entered by authorised staff onto
eCRF with a full audit trail.
Trial Database Website Address http://www.ctu.co.uk
(click ‘studies’ tab)
Database passwords Database access will be strictly
restricted through passwords to the authorised research
team. The trial manager will request usernames and pass-
words from the MH&N CTU. It is a legal requirement
that passwords to the eCRF are not shared, and that only
those authorised to access the system are allowed to do
so. If new staff members join the study, a personalised
username and password should be requested via the Trial
Manager.
Data Handling & Confidentiality/Format of Records
Data will be handled, computerised and stored in accor-
dance with the Data Protection Act, 1998. Participants
will be identified on the study database using a unique
code and initials. The investigator will maintain accurate
patient records/results detailing observations on each
patient enrolled.
Identifiable Data All participant contact/screening and
recruitment data will be will be stored centrally within an
Access database which will have restricted access from
password protected computers, in order to facilitate NHS
Information Centre monitoring and collection of death
certificates. This database will be destroyed at study end.
Accrual data uploaded to the UKCRN portfolio database
will be anonymised and collated by the Trial Manager to
DeNDRoN.
Main Database SAE data will be collected on paper case
report forms (pCRF) and faxed to the MH&N CTU. SAEs
will be transcribed to eCRF. For all other data collected
there will be a mixture of paper and electronic source
documents (to be outlined in the Data Management
SOP) that will be entered onto the main database. The
Principal Investigator will provide an electronic signature
for each patient Case Record Form once all queries are
resolved and immediately prior to database lock, when
instructed to do so by the Trial Manager. The electronic
signoff page will not be available to sites until this time.
Lithium MACRO Database A separate database will
hold details linked to lithium monitoring in which
lithium physicians (unblinded) have 24 hrs after being
made aware of results to enter data.
At the end of the study, essential documentation will
be archived in accordance with sponsor and local
requirements. The retention of study data will be the
responsibility of the Chief Investigator.
On-Site/Central Monitoring The Trial Manager will
conduct on-site/central monitoring. The Data Manager/
Statistician may identify data fields that should be checked
against the source data during site monitoring visits, the
specifics will be outlined in a Data Management SOP.
Where there are data queries the research nurses will be
responsible for resolving the queries. The Trial Manager
will review responses before closing the query.
Assessments/Data Collection Written informed consent
must be obtained prior to screening and any other study
specific procedures taking place.
Proposed frequency and duration of follow-up (Table 2)
is based on considerations for dose adjustment and safety
monitoring, as suggested in the NICE guidelines on
lithium: http://www.nice.org.uk; Guidelines No 38. All
visit dates are calculated from the date of the randomisa-
tion visit (Day 0). Study procedures are listed in Table 3.
Statistical Considerations The Statistical Analysis Plan
will be written and signed off by the TSC and DMEC in
advance of database lock. Data analysis will be per-
formed by the study statistician at Newcastle Clinical
Trials Unit, using a password-protected computer in a
private office.
Statistical Analysis Sensitivity analyses will include per-
protocol and per-treatment analyses, as specified in the
Statistical Analysis Plan to be developed by the Trial
Statistician and approved by the TSC and the DMEC
prior to database lock.
No interim analysis is planned although pre-defined
stopping criteria will be discussed by the Trial Steering
Committee (TSC) and the Independent Data Monitoring
and Ethics Committee (DMEC) and agreed if appropriate.
The population used in the efficacy analyses is the Inten-
tion to Treat (ITT) population. This population will con-
sist of all patients randomised to treatment, who took at
least one dose of double-blind treatment, regardless of
compliance with the study protocol and procedures. If the
primary analysis event (i.e., death) does not occur, a
patient’s data will be considered censored either on his/
her planned study end date, or on the cut-off date for the
study as a whole, or when the patient becomes lost to fol-
low-up, whichever is the earlier. Data will be included in
the analysis regardless of whether the patient is still receiv-
ing double-blind study treatment or complying with the
prescribed regimen. The Trial Steering Committee and/or
Data Monitoring Committee may decide that sensitivity
analyses (endpoints and population to be defined) are also
required. The population used to assess safety and toler-
ability will consist of all patients randomised to treatment
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Table 2 Visit Schedule
Pre-Randomisation Week 3/Day 21 (+/- 3
days)
Week 12 (+/- 7 days) Month 12 (+/- 7 days)
A detailed list of drugs and other agents that might
interact with lithium will be provided to volunteers and to
their general practitioners, together with a list of 24 hour
emergency contact numbers.
Dose monitoring (Li levels) ALS Interventions ALS Interventions
Informed consent Biochemistry ALSFRS-R ALSFRS-R
Registration/Demographics Urine Pregnancy Test
Adverse Events
EQ-5D EQ-5D
SVC Concomitant medications HADS HADS
ALS History Physical Exam (inc vital
signs)
Physical Exam (inc vital
signs)
ALS Interventions Dose monitoring (Li levels) ECG
Medical HistoryNeurological Exam Haematology Dose monitoring (Li levels)
Inclusion/Exclusion Criteria Physical Exam (inc vital signs) Biochemistry Haematology
ALSFRS-R Urine Pregnancy Test
Adverse Events
Biochemistry
EQ-5D Concomitant medications TFTs
HADS Trial Medication Log Urine Pregnancy Test
Adverse Events
ECG Drug Dispensing & Returns Concomitant medications
Dose monitoring (Li levels) Trial Medication Log
Haematology Drug Dispensing & Returns
Biochemistry
Thyroid Function Tests
Urine Pregnancy Test
Concomitant Medications
Adverse Events
Drug Dispensing
Trial Medication Log
Week 1/Day 7 (+/- 3 days) Week 4/Day 28 (+/- 3
days)
Month 6 (+/- 7 days) Month 15 (+/- 7 days)
Dose monitoring (Li levels) Dose monitoring (Li levels) ALS Interventions ALS Interventions
Biochemistry Haematology ALSFRS-R ALSFRS-R
Urine Pregnancy Test Biochemistry EQ-5D EQ-5D
Adverse Events Urine Pregnancy Test
Adverse Events
HADS HADS
Concomitant medications Concomitant medications Physical Exam (inc vital
signs)
Physical Exam (inc vital
signs)
Trial Medication Log ECG Dose monitoring (Li levels)
Drug Dispensing & Returns Dose monitoring (Li levels) Haematology
Haematology Biochemistry
Biochemistry Urine Pregnancy Test
Adverse Events
TFTs Concomitant medications
Urine Pregnancy Test
Adverse Events
Trial Medication Log
Concomitant medications Drug Dispensing & Returns
Trial Medication Log
Drug Dispensing & Returns
Week 2/Day 14 (+/- 3 days) Week 8 (+/- 3 days) Month 9 (+/- 7 days) Month 18/Week 77
(+ 7 days)
Dose monitoring (Li levels) Dose monitoring (Li levels) ALS Interventions ALS Interventions
Biochemistry Haematology ALSFRS-R ALSFRS-R
Urine Pregnancy Test Adverse Events Biochemistry EQ-5D EQ-5D
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that took at least one dose of double-blind treatment and
provided at least some data thereafter, regardless of com-
pliance with the study protocol and procedures. Descrip-
tive statistics of baseline data and summaries of safety and
tolerance data will be further subdivided by randomisation
stratum (site of onset of the disease, centre).
Demographics and population characteristics: Devia-
tions from the protocol, with regard to both the entry cri-
teria and the scheduled assessments and examinations,
will be summarized. Individual deviations will be detailed
and (if appropriate) commented upon. Treatment assign-
ment by stratum and study site, and the numbers of mea-
surements available for each parameter will be presented.
Demographics, medical history, history of the disease,
scores at baseline on all variables and scales assessed, and
medication and other treatment received on entry will be
summarized with tabular presentation of baseline
comparability.
Efficacy
Primary analysis
The primary outcome is survival at 18 months. Survival
rates at 18 months in the two arms (Lithium treatment
versus control) will be compared using a Kaplan-Meier
analysis and log rank test. Results will also be given in
the form of a 95% confidence interval for the relative
risk of survival.
Secondary analysis
Secondary outcomes including the ALSFRS-R will be
assessed at baseline, 3, 6, 9, 12, 15, and 18 months. The
main statistical challenge in analysing such data is to take
into account incomplete data which will be due to a
number of factors most notably of which will be the
death of individual patients; in this study we anticipate
that survival rates may differ by at least 20%. It is neces-
sary to take into account the differing drop out rates and
the non-randomness of the drop out when comparing
functional status between the two groups. This will be
done by jointly modelling the survival data and repeated
measurements data [33]. The survival data are analysed
using a Cox proportion hazards model incorporating ran-
dom effects. Functional outcomes are modelled using
mixed models appropriate for repeated measures. A key
feature of each of these models is that within each of
them it is possible to fit a latent variable that can be con-
ceptualised as the patient’s propensity to experience poor
outcomes (in the context of survival analysis this is
usually referred to as frailty). It is the inclusion of this
latent variable that allows us to adjust our estimates of
the treatment effect to allow for the different rates of
drop out in each group. Both models are estimated
simultaneously; parameter estimates are based on maxi-
mising the joint likelihood over both the survival and
repeated measures data. Within this framework we will
estimate the effect of Lithium treatment on survival and
functional status/quality of life allowing for key baseline
covariates including site of onset of disease and possible
differences between centres. These methods will be
implemented using software that has been developed as
part of an MRC funded programme of work (Grant
G0400615; statistical methodology for longitudinal stu-
dies in clinical research; Williamson PR, Diggle PJ and
Henderson R, unpublished work).
Sample Size Calculation The sample size is based on
detecting a difference in survival rates at 18 months using
Fleiss’ method for a proportion incorporating a continuity
correction. Two groups of 110 subjects will give us 80%
power to detect a difference of 17.5% in survival rates
(65% versus 82.5%) assuming a type 1 error rate of 5%. It
is anticipated that we will have complete survival data on
all subjects recruited. The parameters included in this
calculation were informed by the database of Professor V
Meininger (H&#244;pital PitiéSalpétrière, Paris). The
Table 2 Visit Schedule (Continued)
Concomitant medications Urine Pregnancy Test
Adverse Events
HADS HADS
Concomitant medications Physical Exam (inc vital
signs)
Physical Exam (inc vital
signs)
Trial Medication Log Dose monitoring (Li levels) ECG
Drug Dispensing & Returns Haematology Dose monitoring (Li levels)
Biochemistry Haematology
Urine Pregnancy Test
Adverse Events
Biochemistry
Concomitant medications TFT’s
Trial Medication Log Urine Pregnancy Test
Adverse Events
Drug Dispensing & Returns Concomitant medications
Trial Medication Log
Drug Returns
Unscheduled Visits
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hypothesised difference in survival rates of 17.5% is clearly
clinically very significant but less than that which might be
expected on the basis of previous work [5]. Sample size
was calculated defining survival as death alone (i.e., not
including tracheostomy or Permanent Assisted Ventila-
tion, PAV). Loss of follow-up per year for the primary out-
come measure was set at 0%-in previous studies we have
been able to ascertain survival for all subjects who have
been recruited. In the most recent multicentre European
trial, the unadjusted survival rate for patients with similar
inclusion criteria was ~60% on riluzole alone (V Meinin-
ger, personal communication, unpublished data). For
functional measures, databases from recent large-scale
trials have indicated that the average slope of decrease in
ALSFRS-R score on riluzole plus placebo is approximately
-10 points per year with a variation coefficient ranging
from 1.2 to 1.5 (with SD ranging from 12 to 15 for
ALSFRS-R) [39,40]. Assuming the survival rates stated
above our proposed sample size will give us 88% power to
detect an effect size (or standardised difference) of 0.5 in
our functional measures.
Recruitment Patient recruitment began in June 2009
and the last patient is expected to complete the trial
protocol in November 2011.
Table 3 Table of events-summary of study procedures
Phase Pre-
Randomisation
Double-Blind Treatment
Study Week/month Wk -4 to Day
0
Wk
0
Wk
1
Wk
2
Wk
3
Wk
4
Wk
8
Wk 12/
Mth 3
Mth
6
Mth
9
Mth
12
Mth
15
Mth 18/Wk
77
Withdrawal
Informed consent X
Registration/
Demographics
X
SVC X
ALS History X
ALS Interventions X x x x x x x x x
Medical History X
Neurological Exam1 X
Inclusion/Exclusion
Criteria
X x
Physical Exam (inc vital
signs)
x x x x x x x x x
ALSFRS-R x x x x x x x x
EQ-5D x x x x x x x x
HADS x x x x x x x x
ECG x x x x
Haematology x x x x x x x x x
Biochemistry x x x x x x x x x x x x
Dose Monitoring (Li
levels)
x3 x x x x x x x x x x x x x
Urine pregnancy Test2 x x x x x x x x x x x
Thyroid Function Tests x x x x
Concomitant
Medications
x x x x x x x x x x x x x x
Adverse Events Form x x x x x x x x x x x x x
Trial Medication Log x x x x x x x x x x
Drug Dispensing &
Returns
x x x x x x x x x4 x 4
Patient Medication
Guess
x x
Physician Medication
Guess
x x
Withdrawal Form x
Note: where an “x” is contained within a field this denotes that the associated data will be collected at the identified time point.
1 The neurological exam must be performed by a physician.
2. Women of child-bearing potential only
3. Can be completed at anytime during the screening window but must be completed before patient is randomised.
4. Returns only not dispensing.
Al-Chalabi et al. BMC Neurology 2011, 11:111
http://www.biomedcentral.com/1471-2377/11/111
Page 11 of 14
Discussion
This protocol will allow us to determine if lithium carbo-
nate is effective in ALS as suggested by an earlier study
[5]. Patient recruitment began in June 2009 and the last
patient is expected to complete the trial protocol in
November 2011.
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